Karşıyaka Prevalance and Awareness of Hypertension Study (KARHIP)

Background: The study was planned to assess potential differences in hypertension prevalance and hypertension related demographic properties in an urban area with relatively higher income and cultural population compared to the national average. Methods: Fieldwork was done by educated and dedicated personnel at Karsiyaka Municipality Building by one by one interviewing poll, blood pressure measurement, rhythm and body composition analysis in February 2014. Hypertension was defined as an average systolic blood pressure ≥140 mmHg or an average diastolic blood pressure ≥90 mmHg. Results: Out of a total of 1417 (627 males and 790 females) people enrolled, 780 people were hypertensive (prevalence 55%). Hypertension prevalence in the middle age group (age 35-65) was 46% and in the geriatric age group (age>65) it was %79. 216 out of 780 hypertensive (27.7%) people were not aware of their disease. The proportion of people taking antihypertensive treatment was 69.4% and the proportion under control was 34.7%, whereas the control rate was 50.1% in 541 patients who were aware of their diseases. Conclusions: Hypertension prevalances in our study were similar to the PatenT 2 trial prevalances, which were 46 % for the middle age group and 78% for the geriatric age group. Compared to PatenT 2 data, the rate of hypertension awareness (54.7% vs 72.3%) and the rate of being under treatment (47.5% vs 69.4%) were higher. The rate of controlled hypertension was a little bit higher (28.7 % vs 34.7% ) in our group, whereas control rates in aware and treated groups were similar (53.9 % and 50.1 %) in both studies

Optimization of change in epicardial fat thickness for obese patients who lost weight via the bariatric surgery method using central composite and Box-Behnken experimental designs

Background. The aim of this study was to detect the optimal values for Age, Body Mass Index (BMI) and HOMA-IR of obese patients prior to surgery that results in a maximal decrease of visceral fat mass 6 months after bariatric surgery. Method. In this study, 33 experimental set-ups were designed. This study was approved by Baskent University Medical and Health Sciences Research Board (Approval number: KA16/281). The study data consisted of 40 obese patients who lost weight through the bariatric surgery between February 2015 and December 2016. The values of BMI, Age and HOMA for the obese patients who lost weight through the bariatric surgery were evaluated in three categories and at three levels; the response variable was determined as the Change in Epicardial Fat Thickness (1EFT). Results. As a result of CCD analysis, the optimum 1EFT = 2.571 was determined when Age = 30.52, BMI = 45.30, and HOMA = 34.62. As a result of the BBD analysis, the optimum 1EFT = 3.756 was determined, when Age = 38.36, BMI = 63.18, and HOMA = 14.95. The optimum 1EFT was modeled with Contour and Response Surface plots. Conclusion. Based on the two surface response models used in our study, the maximal decrease of visceral fat mass as assessed by measuring echography images of epicardial fat thickness can be obtained by bariatric surgery of persons who are between 31 and 38 year old, have a BMI between 45 and 63 kg/m2 and have a HOMA-IR 34 between 15 and 35. Central Composite Design and a Box-Behnken Design of suitable patient data predicted 35 optimal settings of independent variables for the maximal clinical response of an intervention

The Safety and Tolerability of Nebivolol in Hypertensive Patients with Coronary Artery Disease and Left Ventricular Ejection Fraction >= 40%: A Population-Based Cohort Study (Nebivolol-TR Study)

Background: This study aimed to assess the safety and tolerability of nebivolol in hypertensive patients with coronary artery disease and left ventricular ejection fraction >= 40% in a Turkish cohort. Methods: A total of 1015 hypertensive patients and coronary artery disease with left ventricular ejection fraction >= 40% were analyzed from 29 different centers in Turkey. Primary outcomes were the mean change in blood pressure and heart rate. Secondary outcomes were to assess the rate of reaching targeted blood pressure (130/80 mmHg) and heart rate (60 bpm) and the changes in the clinical symptoms (angina and dyspnea). Adverse clinical events and clinical outcomes including cardiovascular mortality, cardiovascular hospital admissions, or acute cardiac event were recorded. Results: The mean age of the study population was 60.3 +/- 11.5 years (male: 54.2%). During a mean follow-up of 6 months, the mean change in blood pressure was -11.2 +/- 23.5/-5.1 +/- 13.5 mmHg, and the resting heart rate was -12.1 +/- 3.5 bpm. Target blood pressure and heart rate were achieved in 76.5% and 37.7% of patients. Angina and functional classifications were improved by at least 1 or more categories in 31% and 23.2% of patients. No serious adverse events related to nebivolol were reported. The most common cardiovascular side effect was symptomatic hypotension (4.2%). The discontinuation rate was 1.7%. Cardiovascular hospital admission rate was 5% and hospitalization due to heart failure was 1.9% during 6 months' follow-up. Cardiovascular mortality rate was 0.1%. Conclusion: Nebivolol was well tolerated and safe for achieving blood pressure and heart rate control in hypertensive patients with coronary artery disease and heart failure with preserved or mildly reduced ejection fraction.This study was supported by Baskent University Research Fund.Baskent University Research Fun

Prevalence and Associated Factors of Inappropriate Dosing of Direct Oral Anticoagulants In Patients With Atrial Fibrillation: The ANATOLIA-AF Study (dec, 10.1007/s10557-022-07409-w, 2022)

[No Abstract Available

Karşıyaka Prevalance and Awareness of Hypertension Study (KARHIP)

Background: The study was planned to assess potential differences in hypertension prevalance and hypertension related demographic properties in an urban area with relatively higher income and cultural population compared to the national average. Methods: Fieldwork was done by educated and dedicated personnel at Karsiyaka Municipality Building by one by one interviewing poll, blood pressure measurement, rhythm and body composition analysis in February 2014. Hypertension was defined as an average systolic blood pressure ≥140 mmHg or an average diastolic blood pressure ≥90 mmHg. Results: Out of a total of 1417 (627 males and 790 females) people enrolled, 780 people were hypertensive (prevalence 55%). Hypertension prevalence in the middle age group (age 35-65) was 46% and in the geriatric age group (age>65) it was %79. 216 out of 780 hypertensive (27.7%) people were not aware of their disease. The proportion of people taking antihypertensive treatment was 69.4% and the proportion under control was 34.7%, whereas the control rate was 50.1% in 541 patients who were aware of their diseases. Conclusions: Hypertension prevalances in our study were similar to the PatenT 2 trial prevalances, which were 46 % for the middle age group and 78% for the geriatric age group. Compared to PatenT 2 data, the rate of hypertension awareness (54.7% vs 72.3%) and the rate of being under treatment (47.5% vs 69.4%) were higher. The rate of controlled hypertension was a little bit higher (28.7 % vs 34.7% ) in our group, whereas control rates in aware and treated groups were similar (53.9 % and 50.1 %) in both studies

Azalmış ejeksiyon fraksiyonu olan kalp yetersizliği hastalarında anjiyotensin reseptörü neprilysin inhibitörü: Türkiye’den gerçek dünya deneyimi (ARNi-TR)

Objective: Heart failure (HF) is a growing public health problem with high morbidity and mortality. Recently, angio tensin receptor neprilysin inhibitor (ARNi) has emerged as a promising treatment for HF with reduced ejection fraction (HFrEF). Here, we shared our experience with the use of ARNi in HFrEF from multiple centers in Turkey.Methods: The ARNi-TR is a multicenter, nonintervention al, retrospective, observational study. Overall, 779 patients with HF from 22 centers in Turkey who were prescribed sacubitril/valsartan were examined. Initial clinical status, biochemical and echocardiographic parameters, and New York Heart Association functional class (NYHA-FC) values were compared with follow-up values after 1 year of ARNi use. In addition, the effect of ARNi on number of annual hospitalizations was investigated, and the patients were divided into 2 groups, depending on whether ARNi was ini tiated at hospitalization or under outpatient clinic control.Results: N-terminal pro-brain natriuretic peptide (NT-proB NP), left-ventricle ejection fraction (LV-EF), and NYHA-FC values improved significantly in both groups (all parame ters, p<0.001) within 1-year follow-up. In both groups, a de crease in hemoglobin A1c (HbA1c) values was observed in ARNi use (p<0.001), and a decrease in daily diuretic doses and hospitalizations owing to HF were observed after ARNi use (all comparisons, p<0.001). Hypotension (16.9%) was the most common side effect in patients using ARNi.Conclusion: The ARNi-TR study offers comprehensive re al-life data for patients using ARNi in Turkey. The use of ARNi has shown significant improvements in FC, NT-proB NP, HbA1c levels, and LV-EF. Likewise, reductions in the number of annual hospitalizations and daily furosemide doses for HF were seen in this study